Overall, these results strongly suggest that a direct cross-talk with β1 integrin determines whether sVEGFR1-i13 positively or negatively regulates VEGFR signalling to promote either cell proliferation (resistance) or apoptosis (sensitivity) in response to anti-angiogenic therapies in SQLC tumour cell lines. Here, KDR is linked to neoplasm.